Periodontal Assessment of a Bariatric Care Population
Launched by QUEEN MARY UNIVERSITY OF LONDON · Apr 15, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the oral health of people who are candidates for bariatric surgery, which is a procedure to help with weight loss in individuals with obesity. The main goal is to find out how common and serious gum disease, known as periodontal disease, is among these patients. Additionally, researchers want to learn more about certain factors that could be linked to gum disease, like specific genes and bacteria found in saliva and dental plaque.
To join the study, participants need to be at least 18 years old, have a body mass index (BMI) of 30 or higher, and provide their consent to take part. Those who are pregnant, have certain illnesses, or are taking specific medications may not be eligible. Participants can expect to provide saliva and dental plaque samples for testing, and their overall health and gum condition will be assessed. This research aims to improve our understanding of how obesity impacts oral health and could help develop better care for patients undergoing bariatric surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Each subject must meet all of the following inclusion criteria to be enrolled in the study:
- • 1. Subject must be over 18 years of age.
- • 2. Subject must have a BMI of higher or equal to 30 kg/ m2
- • 3. Subject must have voluntarily given written informed consent.
- Exclusion Criteria:
- Subjects meeting any of the following exclusion criteria are not to be enrolled in the study:
- • 1. Subject is currently involved in other research involving the use of antibiotics or novel or unknown medications.
- • 2. Self-reported pregnancy.
- • 3. Subject is on chronic treatment (i.e., two weeks or more) with specific medications known to affect periodontal status (phenytoin or cyclosporine) within one month of baseline visit.
- • 4. Subject knowingly has HIV or Viral Hepatitis.
- • 5. Patients are completely edentulous.
- • 6. Subject with uncontrolled systemic illnesses.
- • 7. Subject is not capable to give informed consent.
- • 8. Subjects on chronic antibiotic therapy (ie two weeks or more in the previous month).
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luton, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Nikolaos Donos, Prof.
Principal Investigator
Professor of Periodontology and Implantology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials